Track Clearmind Medicine Inc. Common Shares — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Clearmind Medicine Inc. Common Shares CMND · Stock Open Clearmind Medicine Inc. Common Shares in new tab

1.93 USD
Add to portfolio
EPS
-175.92
P/B
0.14
ROE
-114.61
Beta
-1.18
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateJune 11, 2026
EPS-175.92
Book Value11.28
Price to Book0.14
Debt/Equity0.75
% Insiders0.093%

DCF Valuation

Tweak assumptions to recompute fair value for Clearmind Medicine Inc. Common Shares (CMND)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Clearmind Medicine Inc. Common Shares Logo Clearmind Medicine Inc. Common Shares Analysis (CMND)

Canada Health Care Official Website Stock

Is Clearmind Medicine Inc. Common Shares a good investment? Clearmind Medicine Inc. Common Shares (CMND) is currently trading at 1.93 USD.

Earnings Schedule: Clearmind Medicine Inc. Common Shares is expected to release its next earnings report on June 11, 2026.

Investor FAQ

Does Clearmind Medicine Inc. Common Shares pay a dividend?

No, it does not currently pay a dividend.

What asset class is Clearmind Medicine Inc. Common Shares?

Clearmind Medicine Inc. Common Shares is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be June 11, 2026. The company currently has a trailing EPS of -175.92.

Company Profile

Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; and CM-CMND-001 which is in Phase I/IIa clinical trial for the treatment of alcohol use disorder. In addition, the company has a strategic collaboration with SciSparc Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem, Polyrizon Ltd., and NeuroThera Labs Inc. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.

Exchange Ticker
NMS (United States) CMND
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Nov. 28, 2023 0.030000
Dec. 15, 2025 0.030000
May 21, 2026 0.100000
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion